Biocon's shares have risen by 18.31% over the past year. However, year-to-date (YTD), the stock has dropped by 9.59%. In the ...
GlobalData on MSN4d
Biosimilars drive Sandoz growth ahead of unclear tariff effects in 2025Sandoz reported a 9% growth in net sales of generics and biosimilars to third parties for 2024, marking a strong first ...
Biocon Biologics has partnered with Civica to improve access to and affordability of insulin aspart in the U.S. Biocon will ...
The rise in Biocon share price came after the company announced that its wholly-owned subsidiary, Biocon Pharma, has received ...
Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced the successful results of a pivotal Phase 3, ...
Siddharth Mittal, MD and CEO of Biocon said the company will launch Liraglutide in Europe in FY26 along with its partner, ...
Biocon Biologics partners with Civica to enhance access to Insulin Aspart in the US, no tech transfer involved.
This collaboration is in addition to Biocon Biologics’ own insulin aspart drug product for the US, which is currently under ...
Shares of firms like HCL Tech, RailTel, Tata Power, IndusInd Bank, Gensol, and others will be in focus on Monday's trade ...
Biocon Biologics partners with Civica Inc to increase affordability and access to Insulin Aspart in the US, targeting the ...
Nifty March Futures up by 0.08% at a premium of 97.45 points. Nifty Options March 13 Expiry: Maximum call open interest at 20 ...
Civica will commercialize the medicine for patients in the United States, after completion of development work and clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback